Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

10x Genomics (TXG) Non Operating Income (2018 - 2025)

10x Genomics (TXG) has disclosed Non Operating Income for 8 consecutive years, with -$15.7 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income fell 1176.08% to -$15.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$6.9 million through Dec 2025, down 157.11% year-over-year, with the annual reading at $1.0 million for FY2025, 93.89% down from the prior year.
  • Non Operating Income hit -$15.7 million in Q4 2025 for 10x Genomics, down from $4.0 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $10.2 million in Q4 2022 to a low of -$15.7 million in Q4 2025.
  • Historically, Non Operating Income has averaged $990000.0 across 5 years, with a median of $187500.0 in 2021.
  • Biggest five-year swings in Non Operating Income: crashed 9512.5% in 2021 and later soared 203220.0% in 2022.
  • Year by year, Non Operating Income stood at $5000.0 in 2021, then skyrocketed by 203220.0% to $10.2 million in 2022, then fell by 15.5% to $8.6 million in 2023, then crashed by 83.02% to $1.5 million in 2024, then crashed by 1176.08% to -$15.7 million in 2025.
  • Business Quant data shows Non Operating Income for TXG at -$15.7 million in Q4 2025, $4.0 million in Q3 2025, and $2.6 million in Q2 2025.